Anti-Bacillus anthracis pagA/Protective antigen Reference Antibody (Obiltoxaximab, RUO) (JN898016)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	JN898016
Description	Obiltoxaximab (JN898016) is a research-grade recombinant antibody targeting Protective antigen. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Bacillus anthracis
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Chimeric
Isotype	IgG1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P13423
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	ETI-204, 1351337-07-9
Background	Protective antigen (PA/pagA) is a ~85 kDa protein. Protective antigen constitutes one of the three proteins composing the anthrax toxin; it mediates attachment to host cells and translocation of edema factor (EF) and lethal factor (LF) into the host cytoplasm. PA associated with LF forms the lethal toxin (LeTx) and causes death when injected; PA associated with EF forms the edema toxin (EdTx) and produces edema. PA induces immunity to infection with anthrax. 1. Bradley, KA. et al. (2001) Nature 414, 225-9. PMID: 11700562 2. Bradley, KA. et al. (2003) The Journal of biological chemistry 278, 49342-7. PMID: 14507921 3. Santelli, E. et al. (2004) Nature 430, 905-8. PMID: 15243628 4. Lacy, DB. et al. (2004) Proceedings of the National Academy of Sciences of the United States of America 101, 13147-51. PMID: 15326297 5. Singh, Y. et al. (1991) The Journal of biological chemistry 266, 15493-7. PMID: 1651334 6. Mock, M. et al. (2001) Annual review of microbiology 55, 647-71. PMID: 11544370
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SEC-HPLC

SEC-HPLC detection for Research Grade Obiltoxaximab.
Bioactivity

Detects PA/pagA/PA-83 in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Obiltoxaximab
Western blot

Western blot analysis was performed using anti-PA/pagA/PA-83 monoclonal antibody at 1μg/ml on various samples.
Lane 1: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 50ng
Lane 2: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 30ng
Lane 3: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 20ng
Lane 4: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 10ng